Humacyte, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-12
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$1.96M, a 110.93% decline year-over-year.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $17.91M, a 48.91% decline year-over-year.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $35.06M.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$20.20M.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$44.44M, a 406.72% decline from fiscal 2024.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $14.49M.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$68.97M.
- Humacyte, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$67.73M, a 138.14% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.41M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$1.96M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | -$44.44M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | -$75.45M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$6.91M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $17.91M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $14.49M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$9.88M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $13.12M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $35.06M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$68.97M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$49.43M 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | -$35.17M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$20.20M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$67.73M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | -$53.77M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$36.47M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$19.28M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $177.57M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $200.52M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$10.96M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $4.70M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $1.09M 10-K/A · filed 2021-05-14 | -$53.78M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $1.32M 10-Q · filed 2020-11-13 | -$38.25M 10-Q · filed 2021-11-15 |